Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. decreased its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 70.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 181,062 shares of the company's stock after selling 433,282 shares during the quarter. Federated Hermes Inc. owned about 0.08% of Hims & Hers Health worth $4,378,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Quadrant Capital Group LLC purchased a new stake in shares of Hims & Hers Health during the 4th quarter worth approximately $53,000. Envestnet Asset Management Inc. increased its position in Hims & Hers Health by 139.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 78,686 shares of the company's stock worth $1,903,000 after purchasing an additional 45,791 shares during the last quarter. Aviva PLC purchased a new stake in Hims & Hers Health during the fourth quarter valued at $550,000. Integrated Quantitative Investments LLC bought a new position in Hims & Hers Health during the fourth quarter valued at $1,211,000. Finally, Resolute Advisors LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter worth $225,000. 63.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on HIMS. Truist Financial decreased their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Bank of America upped their price objective on Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a research report on Tuesday, March 18th. Morgan Stanley cut Hims & Hers Health from an "overweight" rating to an "equal weight" rating and lifted their target price for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Finally, Piper Sandler lifted their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Hims & Hers Health has a consensus rating of "Hold" and a consensus target price of $38.25.

Hims & Hers Health Stock Performance

Hims & Hers Health stock traded up $0.29 during midday trading on Friday, hitting $27.24. 18,468,782 shares of the company's stock were exchanged, compared to its average volume of 15,291,800. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98. The company has a market cap of $6.05 billion, a PE ratio of 61.91 and a beta of 1.65. The firm has a 50-day moving average of $37.59 and a two-hundred day moving average of $30.56.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. As a group, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Soleil Boughton sold 54,153 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $29.90, for a total transaction of $1,619,174.70. Following the completion of the sale, the insider now owns 165,650 shares in the company, valued at approximately $4,952,935. This represents a 24.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Melissa Baird sold 67,687 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $29.35, for a total value of $1,986,613.45. Following the transaction, the chief operating officer now directly owns 706,872 shares in the company, valued at $20,746,693.20. This represents a 8.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 806,811 shares of company stock valued at $30,999,332. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.